Fractyl Health, Inc. Common Stock (GUTS )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol GUTS
- Company Fractyl Health, Inc. Common Stock
- Price $1.34
- Changes Percentage 32.67
- Change 0.33
- Day Low $1.06
- Day High $1.36
- Year High $3.48
- Year Low $0.83
- Market Cap $94,905,476
- Price Avg 50 EMA (D) $1.22
- Price Avg 200 EMA (D) $1.54
- Exchange NASDAQ
- Volume 74,515,510
- Average Volume 2,006,373
- Open $1.1
- Previous Close $1.01
- EPS -2.15
- PE -0.62
- Earnings Announcement 2025-11-11 20:00:00
- Shares Outstanding $70,824,982
Company brief: FRACTYL HEALTH, INC. COMMON STOCK (GUTS )
- Healthcare
- Biotechnology
- Dr. Harith Rajagopalan M.D., Ph.D.
- https://fractyl.com
- US
- N/A
- 11-30--0001
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
GUTS Corporation News
Fractyl Health, Inc. - Special Call
seekingalpha.com -- Fractyl Health, Inc. - Special Call Company Participants Brian Luque Harith Rajagopalan - Co-Founder, CEO & Director Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Res...
Fractyl Health says experimental procedure helps maintain weight-loss in study
reuters.com -- Fractyl Health said its experimental outpatient procedure helped preserve weight loss after discontinuation of a GLP-1 drug, sending the company's shares 23% higher in premarket trading on Friday....
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock
globenewswire.com -- Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock BURLINGTON, Mass., September 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” o...